Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study (Q51370454)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2011

Language	Label	Description	Also known as
English	Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study	scientific article published in November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

D R Owens

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

R Swallow

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

K A Dugi

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

H J Woerle

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

28

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

11

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

1352-1361

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Incretin-based therapies: viewpoints on the way to consensus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03387.X

21 January 2018

Identifiers

10.1111/J.1464-5491.2011.03387.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21781152

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51370454&oldid=2273948302"